Clinical trials ongoing in ERN-EYE Members Expertise Centers
by Disease
Choroideremia
A Multicenter Prospective Observational "Natural History" Study in Patients With Choroideremia (choroideremia)
CIL 34546-NSR-REP-01 (Choroideremia)
SOLSTICE (Choroideremia)
STAR (Choroideremia)
NIGHT (Choroideremia)
GEMINI (Choroideremia)
THOR (Choroideremia (phenotype + approved molecular diagnosis))
Retinitis pigmentosa
A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)
XOLARIS - Natural history of the progression of X-linked retinitis pigmentosa (X-linked retinitis pigmentosa, Germany)
XOLARIS - Natural history of the progression of X-linked retinitis pigmentosa (X-linked retinitis pigmentosa, France)
XOLARIS- Natural history of the progression of X-linked retinitis pigmentosa (X-linked retinitis pigmentosa, UK)
XIRIUS (X-linked RP)
Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A) (Retinitis pigmentosa, Usher Syndrome)
Retinitis pigmentosa: molecular diagnosis by next generation sequencing (inherited retinal dystrophy)
Therapeutic management of patients with cystoid macular edema secondary (retinitis pigmentosa)
Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) (Retinitis pigmentosa; Inherited Retinal Disease caused by Mutation in RPE65 or LRAT genes)
VITAL (USHER syndrome induced by MYO7A mutation and retinotosis pigmentosa)
Argus® II Retinal Stimulation System Feasibility Protocol (retinotosis pigmentosa)
Argus® II Retinal Prosthesis System: Post-Market Study (retinotosis pigmentosa)
Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B (Retinitis Pigmentosa Associated With Usher Syndrome Type 1B)
Clinical implication of Retinitis Pigmentosa molecular diagnostic using high throughput sequencing (RP-SEQ-HD)
Leber syndrome
An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (Leber hereditary optic neuropathy)
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (RESCUE) (Leber hereditary optic neuropathy)
Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON) (Leber's Hereditary Optic Neuropathy)
REVERSE (Leber hereditary optic neuropathy (LHON))
Historical Case Record Survey of Visual Acuity Data From Patients With Leber’s Hereditary Optic Neuropathy (LHON)
Neurotrophic Keratitis
Evaluation of safety and efficacy of r-hNGF (Neurotrophic Keratitis)
Stargardt Disease
Natural History of the Progression of Atrophy Secondary (Stargardt Disease type 4)
Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular Degeneration (Stargardt's disease)
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration (Stargardt's disease)
Hereditary retinal disease
CURETINA (hereditary retinal degenerations caused by mutations in genes CRB1, CRX, PROM1)
RET-IRD-04 (LCA RPE65)
ReCOVER (This trial does use Clemastine fumarat as a remyelinating agent targeting the muscarinic receptor on oligodendrocytes around the optic nerve)
CNGA3-linked achromatopsia
CNGA3 (CNGA3-linked achromatopsia)
Argus II
Argus II retinal prosthesis system post- market surveillance study protocol (inherited retinal dystrophy & choroidal dystrophy)
Argus® II Retinal Stimulation System Feasibility Protocol (retinotosis pigmentosa)
Argus® II Retinal Prosthesis System: Post-Market Study (retinotosis pigmentosa)
Glaucoma
Long-Term Non-Interventional Latanoprost Study (LYNX) (congenital glaucoma)
Usher Syndrome
VITAL (USHER syndrome induced by MYO7A mutation and retinotosis pigmentosa)
Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A) (Retinitis pigmentosa, Usher Syndrome)
Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B (Retinitis Pigmentosa Associated With Usher Syndrome Type 1B)
Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B (Usher Syndrome)
Light4deaf study: study of the natural history of the syndrome of usher in a cohort of patients followed longitudinally for 5 years (Usher Syndrome)
Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B (Retinitis Pigmentosa Associated With Usher Syndrome Type 1B)
Chorioretinopathy
SPECTRA trial (central serous chorioretinopathy)
Retinal dystrophy
Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) (retinal dystrophy)
Nanometer-controlled cut-off filters in real-life self-reported quality of vision of patients with retinitis pigmentosa (inherited retinal dystrophy)
Riluzole in patients with spinocerebellar ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase
Natural History Study of CEP290-Related Retinal Degeneration
Congenital cataract registry
Factors affecting sight development in congenital cataract patients (congenital cataract registry)
Alström Syndrome
Clinical Study of a single ciliopathy: Alström Syndrome
Trisomy 21
Trisomy 21 in Adulthood : a medical and social situation in Alsace
| Legal | Site by 2exVia with MasterEdit®